Study population and setting
The study population was comprised of 273 patients with laboratory-confirmed SARS-CoV-2 infection from a single hospital in Wuhan, China who were admitted between January 1, 2020 and February 18, 2020. Among these patients, 198 were classified as having mild clinical disease, 60 with severe disease, and 15 with critical disease.
Summary of Main Findings
At admission, 12% of patients presented with elevated levels of brain natriuretic peptide (NT-proBNP), 10% with elevated myoglobin, 10% with elevated troponin I, and 4% with elevated creatinine kinase (CK-MB). Of the biomarkers, myoglobin, troponin I, and NT-proBNP appear to be differentially elevated with more severe illness presentations. Patients presenting with abnormal cardiac laboratory parameters had more than four times the mortality ratio as those without (23% vs. 5%).
As there are no data presented on pre-infection health and comorbidities of participants, it is not possible to attribute the rise in cardiac biomarkers to the infection. This is particularly true with high-sensitivity troponin and BNP assays that may be chronically elevated. There is no information presented on the prognostic utility of specific threshold biomarker values. Further, cardiac biomarkers may be elevated in the setting of hypoxia or shock; there is insufficient information presented to allow for the evaluation of the prognostic role of isolated cardiac biomarkers.
This study presents data on cardiac injury biomarkers in a reasonably large study population of patients with COVID-19.